Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme

Abstract

The safety and efficacy observed were consistent with those reported in the pivotal Checkmate 025 trial. Results in patients with non-clear-cell mRCC who were elderly, pretreated with everolimus, and had bone and/or brain metastases encourage the use of nivolumab in these categories of patients.